Goldman Sachs made significant rating changes across its U.S. biopharma coverage on Tuesday, upgrading the likes of Eli Lilly ...

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

Goldman updates coverage across major U.S. drugmakers, citing exclusivity risks, pricing power, and pipeline outlooks ...

Goldman Sachs analyst Asad Haider assumed coverage of AbbVie (ABBV) with a Neutral rating and $194 price target The company’s “strong” growth ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on AbbVie (ABBV) to $241 from $239 and keeps an Overweight rating on the ...

The new approval consolidates Imbruvica’s position in CLL, which is co-marketed by J&J and AbbVie and made sales of $2.61 billion and $3.59 billion respectively for the partners last year.

Imagine standing on a vast, dark plain. Without light, you cannot see dips and rolls in the grass or make out hills and valleys. Even if there’s a city off in the distance to your right, it does ...

April 3 (Reuters) - AbbVie (ABBV.N), opens new tab on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition expenses related to milestone ...

Apheris’ consortium of pharma companies is partnering with OpenFold3 — Columbia professor Mohammed AlQuraishi’s open-source dupe of AlphaFold3 — to train the model on AbbVie and Johnson ...

Upgrading J&J (NYSE:JNJ) to Buy from Neutral ... However, Haider downgraded AbbVie (NYSE:ABBV) to Neutral from Buy, and trimmed its 12-month price target to $194 from $212 per share, arguing ...